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Microgravity Effects on the Human Body
Life Sciences Research Laboratories (Bldg. 37)
•Immunology Laboratory
•Nutrition Laboratory
•Radiation Laboratory
•Microbiology Laboratory
•Neurovestibular Laboratory
•Clinical Laboratory
•Muscle Laboratory
•Bone Laboratory
•Toxicology Laboratory
•Cardiology Laboratory
Mars Departure
Earth Departure
Overview of Hypothetical Mars Expedition
Based on: Human Exploration of 
Mars, DRA 5.0, NASA-SP-2009-
566, July 2009
Earth Arrival
Mars Arrival
Earth-to-Mars transit:   ~6 months
Mars surface stay: ~18 months
Mars-to-Earth transit:   ~6 months
Recent changes to NASA vehicle plan
Pre-2010
Program Constellation
Rockets Ares-1
Ares-V
Vehicles Orion, Altair
(Shuttle)
Destination Moon, eventually Mars
Recent changes to NASA vehicle plan
Current
Program
Rockets NASA - Heavy Lift
Commercial:
Falcon 9, Taurus 2
Vehicles NASA: Orion
Commercial:  Dragon, 
Cygnus
Destination TBD, Asteroids?
Feasible Exploration 
Vehicles
Impacts of Physiological Adaptation
• Space flight-induced changes can 
affect operations during flight or 
crew function upon return to Earth 
• They may also be deleterious to 
long term crew health
• These factors must be thoroughly 
understood and mitigated where 
possible in order to manage 
mission and crew health risks
Critical Mission Tasks
• EVA capability
• Nominal and contingency 
return
• Nominal and contingency 
egress
• Rapid post-flight return to 
nom ops 
• Long term health issues
Human Research on ISS by HRP
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NASA Human Research Roadmap
•Guides all NASA ground/analog/flight human research
•Orients funded science towards prioritization for enabling 
exploration-class space missions
•Framework of defined/approved ‘Clinical Risks’, 
‘Knowledge Gaps’, ‘Tasks’
•All new proposals are directed to map against HRP 
knowledge gaps
•Ongoing internal and external reviews ensure NASA 
research maintains focus towards closing knowledge gaps, 
mitigating risks, enabling exploration.
Human Research on ISS
• Establish an evidence base on crew 
health and performance for long 
duration missions in reduced gravity
• Identify greatest risks and develop 
optimal approach to mitigations and 
countermeasures 
• Test space biomedical technology and 
medical care procedures
• Actively collaborate and share 
resources with the International 
Partners on space biomedical research
Bone
BONE ISSUE FOR SPACEFLIGHT
•Weakening of the bones due to the progressive loss of bone mass is a potentially 
serious side-effect of extended spaceflight
•Studies of cosmonauts and astronauts who spent many months on space station Mir 
revealed that space travelers can lose (on average) 1 to 2 percent of bone mass each 
month
•Spacefarers typically experience bone loss in the lower halves of their bodies, 
particularly in the lumbar vertebrae and the leg bones. 
•Diminishing bone mass also triggers a rise in calcium levels in the blood, which 
increases the risk of kidney stones.
Cortical Bone/ “Compact Bone”
PROXIMAL FEMUR
VERTEBRAL BODY
Cancellous “Spongy” Bone/Trabecular Bone
Trochant
er
Femoral 
Neck
•But bones are actually dynamic living tissues that constantly reshape themselves in 
response to the stresses placed on them
•Two cell types, "osteoblasts" and "osteoclasts" are constantly building or destroying 
bone.  Usually these actions balance each other out. But when stresses on bones are 
reduced, removal outpaces replacement, leading to too little bone which can more 
easily break.
What is wrong?
•In prolonged weightlessness, 
bone mass decreases because 
the lack of stress on the bones 
slows the formation of 
osteoblast cells. 
•Fewer bone-building cells, 
along with a constant level of 
bone-destroying activity, 
translates into a net loss of bone 
mass.
Bone turnover markers suggest that  bone degradation is 
increased, formation is uncoupled from resorption, and 
bone gain and loss are unbalanced averaged over entire 
skeleton 
(Smith et al, JBMR 2005)
More bone mass is subtracted FROM than added TO the skeleton.

Recovery of BMD with return to gravity
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Trochanter BMD of ISS & Mir Crewmembers
Loss0=7.4% Recovery Half-life=276 d
What did we learn?
• Confirmed overall bone loss rates of 1-1.5% per month in wt 
bearing bones
• Trabecular bone loses mineral significantly faster than the 
cortical bone (approx 2X)
• Overall bone density slow to recover
• Recovered structure not the same as original and may have 
less total strength
• Med ops taking several actions based on these findings
– Following crew for longer post-flight with DXA and QCT
– Developing a strategy for FEA modeling to determine 
strength levels
– Further collaboration with research side for the Mayo 
cohort study to determine long term fracture risks
Neurovestibular
Gravity provides the CNS a 
fundamental reference for estimating 
Role of Gravity (II)
spatial orientation and coordinating 
movements. 

Space Motion Sickness
 0% on Mercury/Gemini
 30% on Apollo/Vostok/Soyuz/Salyut 
 56% on Skylab
 75% on Shuttle
 Incidence is
– highest in larger spacecraft.  
– highest on days 1-2, declining on days 3-5
– lower on second and subsequent space flights. 
– unrelated to gender, or prior flying experience.
– so far, not reliably predicted by 1-g motion sickness 
susceptibility tests.
 “Earth Sickness” (part of “Landing Syndrome”) about 30% 
after 1-2 week missions, 90% after long duration flights.
Spatial Disorientation
0-g Entry Illusions
Inversion Illusion
Visual Reorientation 
Illusion
EVA Height Vertigo0-g Navigation Problems
Courtesy of C. Oman
1-g adapted CNS
CNS Response to Spaceflight 
sensory conflict
loss of gravity cues
entry into sustained 0-g
• disorientation 
• perceptual illusions
• malcoordination
space motion sickness
CNS adaptation
• reinterpretation of sensory inputs 
• new sensory-motor control strategies
• new spatial orientation schemes
0-g adapted CNS
spatial 
orientation
motor
control
brain stem/cerebellum
cerebral cortex
m
o
t
o
r
 
c
o
m
m
a
n
d
s
Human Sensory-Motor Balance Control
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Functional Neurological Assessment
Sensory Organization Test 5 – Head Erect/Head Moving
Long Duration Flight Balance Control Recovery
70
80
90
100
Unstable Support Surface,  Eyes Closed (SOT 5)
Expeditions 1 - 24 (US Crewmembers)
Head Moving (n=26)
Astronaut Recovery (50%, 95%) for Head Erect Condition (shown for comparison)
Head Erect (n=39)  
Eyes closed on unstable surface shows moderate-to-severe deficits post-
flight. Addition of head movements (open symbols) reveals greater inter-
subject variability with longer return to baseline conditions.
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Dynamic Visual Acuity
Landolt-C 
Courtesy of J. Bloomberg, NASA JSC
Manual Control
Flight: Shuttle, SLS-2, n=4, 2 on R+0
Task: Subjects asked to null out roll tilt in a Link 
flight simulator, in darkness, with Earth-fixed 
visual field, and with independent visual field 
motion
Subjects used control wheel to “keep themselves 
upright with respect to gravity”. Sum-of-sines 
motion profile (0.014 – 0.668 Hz)
Merfeld et al., JAP 81((1): 50-57, 1996
Measurement: Manual control error.
Summary:
2 of 2 subjects exhibited significant decrements 
on R+0 in performance in the dark (all 4 subjects 
returned to pre-flight levels by R+2)
Implications: Sensorimotor changes may lead to 
disruption in piloting and driving performance.
What have we learned?
• Space flight induces an adaptation in the sensory motor 
system appropriate for operation in microgravity
• CNS  must re-learn cues and controls for terrestrial 
activity
• These changes vary in intensity and outcome for 
different individuals
• Training can expedite the  transitions and 
pharmacological agents can modulate adverse 
symptoms
• Objective predictors for performance in complex 
environments must continue to be developed
Cardiology
•Cardiac atrophy (a decrease in the size of the heart muscle) appears to 
develop during space flight or its ground-based analogues leading to 
diastolic dysfunction (abnormal left ventricular function in the heart) and 
orthostatic hypotension (drop in blood pressure upon standing). 
•Such atrophy may have been a potential mechanism for the cardiac 
arrhythmias (irregular heart rhythms) identified in some crewmembers 
after long-duration exposure to microgravity aboard the Mir Space Station. 
CARDIAC ISSUE FOR SPACEFLIGHT
•Recent studies suggest that cardiac atrophy may be progressive, without 
a clear plateau over at least 12 weeks of bedrest, and thus may be a 
significant limiting factor for extended duration space exploration 
missions.
•Atrophy may result in impaired cardiac 
function and/or fainting (orthostatic 
intolerance) post-landing on the Earth, 
moon or Mars.
Current NASA research aims to 
determine the significance of cardiac 
atrophy and identify its mechanisms. 
The functional consequences of this 
atrophy are being determined for 
cardiac filling dynamics, orthostatic 
tolerance, exercise tolerance, and 
arrhythmia susceptibility.
‘Integrated Cardiovascular’
The Integrated Cardiovascular experiment investigates the magnitude of ventricular 
atrophy using MRI, relates this type of atrophy to measures of physical activity and 
cardiac work inflight, and determines the time course and pattern of the progression of 
cardiac atrophy cardiac ultrasound.
This investigation also determines the functional importance of cardiac atrophy for 
cardiac diastolic function and the regulation of stroke volume (volume of blood pumped 
by the heart in one contraction) during gravitational transitions, as well as identifies 
changes in ventricular conduction, depolarization and repolarization during and after 
long-duration space flight, and relates these factors to changes in heart mass and 
morphology (shape and form). 
Nicole Stott performs routine tasks 
aboard the ISS while ECG (using 
the HRF Holter Monitor 2) and 
continuous blood pressure data 
(using the ESA Cardiopres) are 
recorded for the Integrated 
Cardiovascular experiment.
Nutrition
Bone
Muscle
Cardio
Fluid/Electrolyte
Immunology
Hematology
Neurovestibular
Endocrine
GI
Energy 
CHO (fiber), Fat, Protein
Fat-soluble vitamins
Water-soluble vitamins
Minerals
Fluid
Systems
Space Nutrition
Nutrient
Requirements                     
  
  
BHP
Vision
Energy
Amino acids
Protein
Sodium
Fatty acids
Antioxidants
Other
Bisphosphonates
KCitrate
Other Meds
Exercise
Other
Duration
Food System
Radiation
EVA
Schedule
Vehicle/Mission
Countermeasures
Nutrition is critical for any type of exploration mission, and is 
multifaceted.
Dietary Intake
Maintaining dietary intake during flight is very important.  Inadequate intakes are 
associated with greater bone and muscle loss, altered cardiovascular 
performance, and other health risks.  Intake for ISS crewmembers is tracked with 
a computer-based Food Frequency Questionnaire (above).
Vitamin D
Vitamin D intake is critical for astronauts, where the food system does not provide 
adequate amounts, and the crews are shielded from ultraviolet light.
Supplementation with 800 IU vit D/day maintains status during flight (left panel).
Antarctic studies show vitamin D, stress, and viral reactivation are interrelated.
Omega-3 Fatty Acids
Fish intake is associated with lower bone loss. Fish, and omega-3 fatty acids in 
particular, may mitigate bone and muscle loss, cardiovascular, and cancer risks.
Radiation
The Space Radiation Problem
Space radiation is 
comprised of high-energy 
protons and heavy ions 
(HZE’s) and secondary 
protons, neutrons, and 
heavy ions produced in 
shielding
– Unique damage to 
biomolecules, cells, and 
tissues occurs from HZE ions
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– No human data to estimate 
risk
– Expt. models must be 
applied or developed to 
estimate cancer, and other 
risks
– Shielding has excessive costs 
and will not eliminate 
galactic cosmic rays (GCR)
Space Radiation Environments
• Galactic cosmic rays (GCR) 
penetrating protons and heavy nuclei -
a biological science challenge
– shielding is not effective
– large biological uncertainties limits 
ability to evaluate risks and 
effectiveness of mitigations
• Solar Particle Events (SPE) largely 
medium energy protons – a shielding,  
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operational, and risk assessment 
challenge
– shielding is effective; optimization 
needed to reduce weight
– improved understanding of radiobiology 
needed to perform optimization
– accurate event alert and responses is 
essential for crew safety
44
GCR a continuum of ionizing radiation types
Solar particle events and the 11-yr solar cycle
GCR Charge Number
Categories of Radiation Risk
Four categories of risk of concern to 
NASA: 
– Carcinogenesis (morbidity and 
mortality risk)
– Acute and Late Central Nervous 
System (CNS) risks
Lens changes in cataractscataracts
 immediate or late functional 
changes 
– Chronic & Degenerative Tissue 
Risks
 cataracts, heart-disease, etc.
– Acute Radiation Risks – sickness 
or death
First experiments for leukemia induction with GCR
IMMUNOLOGY
•One of largest tissues in the human body, 
although largely in fluid state.
•Consists primarily of white blood cells 
(WBCs) located in lymph nodes and the 
peripheral blood. 
•Responsible for protection against viral 
THE IMMUNE SYSTEM
and bacterial infection, latent viral 
reactivation, tumor surveillance, wound 
healing, etc.
•Dysregulation can result in increased 
infection rate, malignancy, autoimmunity, 
allergy, etc.
Overview:  Spaceflight-Associated Immune Dysregulation
Number Infectious Disease
8 Fever, chills
5 Fungal infection
3 Flu-like syndrome
4 Urinary tract infections
3 Aphthous stomatitis
Shuttle:  Incidence of In-flight Infectious Disease
(STS-1 through STS-108 )
2 Viral gastrointestinal disease
2 Subcutaneous skin infection
2 Other viral disease
29 Total incidents in 106 Shuttle flights
Based upon post-flight medical debriefs [Longitudinal study of Astronaut Health] 
by Dr. Kathy Johnson, NASA-JSC
CELLS OF THE IMMUNE SYSTEM
Post-flight observations
-Altered circulating leukocyte 
distribution
Altered cytokine production 
In-flight cell culture
-Intracellular signaling, 
cytoskeleton rearrangement, 
microtubule organizing center 
orientation, generalized 
proliferative responses all altered 
during flight.
Short duration
Reactivation of latent herpesviruses
-EBV, CMV, VZV reactivation during flight
-Infectious VZV particles secreted in saliva
Humoral immunity
-Immunization with antigen 
generates normal antibody 
response during flight
(MIR-18)
patterns (secreted, intracellular, 
Th1/Th2)
-Decreased NK cell function
-Decreased granulocyte function
-Decreased T cell function*
-Altered immunoglobulin levels
-Latent viral reactivation
-Altered virus-specific immunity
-Expression of EBV IE/late genes*
-Altered neuroendocrine 
responses
Reduced cell mediated immunity
-CMI Multitest, common recall 
antigens, long duration flight
Long duration
*Post-flight observations differ between 
long vs. short duration space flight.
SKYLAB IMMUNE DATA - 1973
MODELED 
MICROGRAVITY
1xG CONTROL
Red:  Actin localization
Green:  Microtubules/MTOC
-Mayra Nelman-Gonzalez/JSC
Latent Virus Reactivation
• Herpesviruses and polyomaviruses are 
common latent viruses
– Ubiquitous
– important infectious disease risks
– oncogenic potential
• Risk not mitigated by preflight quarantine
• Space flight stress alters immune response
• Diminished immunity results in reactivation 
and dissemination (“shedding”) of latent 
viruses
• May serve as an early predictor of medically 
significant changes in immune response
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Viral Reactivation During Spaceflight
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-D. Pierson, 2003
Current Flight Study
RECENT SPACE IMMUNE STUDIES
Russian Med-Ops/
CYTOKINE DSO-501 (ISS)
L-60 L-10 R+0 R+7 R+14
Latent Virus/
DSO-493 (SHUTTLE)
L-180 L-10 saliva saliva R+0 saliva saliva
saliva
R+14
Immune Function/
DSO-498 (SHUTTLE)
L-10 R+0 R+21
Japan Immunology/
DSO-206 (SHUTTLE)
L-60 L-30 R+0 R+3 R+7 R+30 R+90
Epstein Barr/
L-120 L-65 L-10 L-3/2 R+0 R+3 R+14
AME/
DSO-500 (SHUTTLE) R+120
Epstein Barr/
E129 (ISS)
AME/
L-180
L-60 L-10 L-3/2 R+0 R+3 R+14
AME/
R+180
Immuno- ESA/
(ISS/SOYUZ)
L-30
L+90 to 
L+120
R-15 to 
R-7
R+1 R+7 R+28
Integrated Immune/
SDBI-1900 (SHUTTLE)
AME**/
L-180
L-10** R-1 R+0** R+14
Integrated Immune/
SMO-015 (ISS)
AME**/
L-180
L-30**
MD
8-10
MID* R-1 R+0** R+30**
IN-FLIGHTPRE-FLIGHT POST-FLIGHT
*If possible via visiting Shuttle mission.  Samples would be collected from the ISS crew and returned on the Shuttle.
** In conjunction with Med-Ops draw.
• Leukocyte subsets
• T cell function
• Intracellular/secreted cytokine 
profiles
• Plasma cytokine balance
• Leukocyte cytokine RNA
JSC 
Immunology 
Laboratory
Mercer 
University
Assays
• Virus specific T cell number
• Virus specific T cell function
• Plasma stress hormones
• Latent herpesvirus 
reactivation (saliva/urine)
• Saliva/urine stress hormones
• Circadian rhythm analysis
Microgen 
Laboratories
JSC 
Microbiology 
Laboratory
Samples - Timepoints
Flight Hardware
Cell Distribution Cell Function
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Immune dysregulation during long-duration spaceflight 
(SMO-015 mid-study data; n=10)
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Cytotoxic CD8+ T cell function CD4+ T cell function CD8+
IL-10 (CD3/CD28) IL-6 (PMA-I) TNFa (PMA-I)

Go Forward Plan…
•Define ‘space normal’ for immunity
•Validate a monitoring strategy
•Perform clinical relevance studies using terrestrial patient 
populations
•Determine clinical risk for immune dysregulation during 
spaceflight (context of exploration class missions)
•Determine the best available ground 
analog for immune dysregulation (feeds 
both data regarding mechanism and a 
platform to validate countermeasures)
•If necessary proceed to countermeasures 
validation (both ground and flight)
SPACEFLIGHT GROUND ANALOGS
-Simulate some aspects of spaceflight on Earth 
for research purposes.
-Routinely used for: 
human physiology research
What are GROUND BASED SPACEFLIGHT ANALOGS?
development of a monitoring strategy 
investigation of mechanism
countermeasures development/validation. 
-Useful considering the microgravity restrictions 
on flight hardware.
Extended head-down bed rest MARS-500  (IBMP – Moscow) Closed Chamber Confinement
Ground-based Space Flight Analogs
NEEMO Aquarius Station Antarctica winter overHaughton-Mars Project
Bed Rest + Artificial Launch/Landing Stress
Bed Rest + Artificial Gravity as a Countermeasure
FLIGHT-RELATED
-Radiation
-Microgravity
WHAT CAUSES IMMUNE CHANGES 
DURING SPACEFLIGHT?
MISSION-ASSOCIATED
-Physiological stress
-Confinement
-Prolonged isolation
-Altered microbial environment
-Altered nutrition
-Disrupted circadian rhythms
•Simulated (or actual) mission-deployment
•Mission/exploration activities
•Intra-vehicle/extra-vehicle activities
•Associated health risk
Analog Usage:
Best Analog for Immune Dysregulation?
•Adverse environment
•Isolation
•Psychological stress
•Physiological stress,
•Disrupted circadian rhythms, etc.
NEEMO Aquarius Station
(Key Largo - Florida)

NEEMO Immune Data:  N12, 13, 14 Pilot Study
http://www.nasa.gov/mission_pages/NEEMO/index.html
Haughton-Mars Project
(High Canadian Arctic – Devon Island)
Haughton Crater
HMP BASE CAMP
FMARS HAB
HMP 2002 Pilot Study
www.marsonearth.org

Concordia Station as Spaceflight-Planetary Exploration Analog
•Difficult travel in/out
•Extreme isolation, even greater than ISS
•Altitude 3200m (10,500 ft)
•Air pressure 645hPa (mbar) = chronic 
hypobaric hypoxia
•Oxygen content ~half sea level
•Lack of CO2 in air
•Higher ionization in air (increases 
oxidative metabolism)
•Relative humidity 3-5%
•Snowfall ~1cm/yr
•High winds
•Elevated UV exposure (summer)
•Mean winter temperature -60 C (-72 F)
•Mean summer temperature -30 C (-22 F)
•Disrupted circadian rhythms
•Altered nutritional aspects  


PRE-FLIGHT IN-FLIGHT POST-FLIGHT
BLOOD B B B B B B B
SALIVA (liquid) L L L L L L L L L L L L L L L L L L L L L L L L L L L L
SALIVA (dry book) D D D D D D D
URINE U U U U
l l l l l l l
L-180/ L-45 MD 8-10* MID-MISSION* R-1 R+0 R+30
A.M.E.
KEY:
B Single blood collection
L Single liquid saliva collection in A.M.
D Single day of dry saliva collections (5 throughout day)
U Single 24 hour urine collection (void by void).
*Early/mid ISS samples to be collected only if sample return possible by other returning/visiting Shuttle/Soyuz vehicle.
All ground blood collections coincide with AME or Med-Ops draws when possible.
Shuttle or Soyuz undocking occurs.  ISS crew (staying 
on station) to be sampled during last full day of docked 
operations.  Samples to be returned on Shuttle/Soyuz.
INTEGRATED IMMUNE
CHOICE
JAN FEB MAR APR MAY JUNE JULY AUG SEPT OCT
~1 month
CONCORDIAPre Post
WB, urine, saliva
WB, urine, salivaFrozen plasma, urine, saliva
Early WO
#1
WO
#2
WO
#3
WO
#4
WO
#5
WO
#6
WO
#7
WO
#8
Late R+30L-60
NASA/ESA Concordia/Antarctic Immune Study
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Mars-ISS Analog Mission Concept
Use ISS as test platform to reduce risk to humans of Mars transit 
mission (outbound or return) and Mars surface transition
• ISS as high-fidelity, cost-effective simulation of eventual Mars 
mission: personnel (flight, ground); vehicle; environment; perceived 
risk; meaningful work.  
• Limitations: Earth outside window; infrastructure (resupply timing;  
real-time MCC monitoring);capability to break simulation when 
necessary.
• Near-Term
– Assess and reduce crew health and mission risks such as weightless 
deconditioning, crew autonomy, communication delays, planning and 
execution, and new technologies
– Exploit ISS as unique testbed providing weightlessness and 
psychological factors not available in other analogs
• Longer-Term
– Full Mars (or NEO) mission duration (900 days)
– Expanded landing site exploration activities
86


For more information…
http://www.nasa.gov/exploration/humanresearch/
http://humanresearchroadmap.nasa.gov/
http://www.nasa.gov/offices/education/programs/descriptions/Students-rd.html
Questions?
